Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

被引：0
|
作者：
Ruth M. de Tute
Gordon Cook
David A. Cairns
Julia M. Brown
Jamie Cavenagh
A. John Ashcroft
John A. Snowden
Kwee Yong
Eleni Tholouli
Matthew Jenner
Anna Hockaday
Mark T. Drayson
Treen C. M. Morris
Andy C. Rawstron
Roger G. Owen
机构：
[1] Leeds Teaching Hospitals Trust,Haematological Malignancy Diagnostic Service
[2] University of Leeds,Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research
[3] Barts & The London NHS Trust,Department of Haematology
[4] Mid-Yorks NHS Trust,Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & Department of Endocrinology & Metabolism
[5] University of Sheffield,Department of Haematology
[6] University College London,Department of Clinical Haematology, Manchester Royal Infirmary
[7] Manchester Foundation Trust,undefined
[8] University Hospital Southampton NHS Foundation Trust,undefined
[9] Institute of Immunology and Immunotherapy University of Birmingham,undefined
[10] College of Myeloma,undefined
来源：
Bone Marrow Transplantation | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 434
页数：3
相关论文
共 50 条
  • [31] Autologous stem cell transplantation for relapsed and primary refractory myeloma
    Rajkumar, SV
    Fonseca, R
    Lacy, MQ
    Witzig, TE
    Lust, JA
    Greipp, PR
    Therneau, TM
    Kyle, RA
    Litzow, MR
    Gertz, MA
    BONE MARROW TRANSPLANTATION, 1999, 23 (12) : 1267 - 1272
  • [32] The relevance of minimal residual disease after autologous stem cell transplantation in patients with multiple myeloma (first results of a prospective study)
    Solovev, M.
    Mendeleeva, L.
    Galtseva, I.
    Pokrovskaya, O.
    Firsova, M.
    Nareyko, M.
    Kuzmina, L.
    Gemdzhian, E.
    Savchenko, V.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S506 - S507
  • [33] Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
    Popat, Rakesh
    Cavenagh, James D.
    Owen, Roger G.
    Streetly, Matthew
    Schey, Stephen A.
    Koh, Mickey
    Crowe, Josephine
    Quinn, Michael F.
    D'Sa, Shirley
    Virchis, Andres
    Cook, Gordon
    Crawley, Charles
    Pratt, Guy
    Cook, Mark
    Oakervee, Heather E.
    Counsell, Nicholas
    Adedayo, Toyin
    Evans, Alison
    Braganca, Nivette
    Smith, Paul
    Lyons-Lewis, Janet
    Rabin, Neil
    Yong, Kwee L.
    BLOOD, 2014, 124 (21)
  • [34] Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization
    Portuguese, Andrew J.
    Yeh, Albert C.
    Banerjee, Rahul
    Holmberg, Leona
    Wuliji, Natalie
    Green, Damian J.
    Mielcarek, Marco
    Gopal, Ajay K.
    Gooley, Ted
    Stevenson, Philip
    Cowan, Andrew J.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (08): : 774e1 - 774e12
  • [35] Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD)
    Solovev, Maxim V.
    Mendeleeva, Larisa P.
    Pokrovskaya, Olga S.
    Gemdzhian, Eduard G.
    Kuzmina, Larisa A.
    Firsova, Maya
    Galtseva, Irina
    Davydova, Julia
    Savchenko, Valeri G.
    BLOOD, 2016, 128 (22)
  • [36] MINIMAL RESIDUAL DISEASE (MRD) RATIO BEFORE AND AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Antonioli, E.
    Nozzoli, C.
    Staderini, M.
    Boncompagni, R.
    Caporale, R.
    Peruzzi, B.
    Bosi, A.
    Saccardi, R.
    HAEMATOLOGICA, 2019, 104 : 66 - 66
  • [37] Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study
    Hahn, Theresa E.
    Wallace, Paul K.
    Fraser, Raphael
    Fei, Mingwei
    Tario, Joseph D.
    Howard, Alan
    Zhang, Yali
    Blackwell, Beth
    Brunstein, Claudio G.
    Efebera, Yvonne A.
    Geller, Nancy
    Giralt, Sergio A.
    Hari, Parameswaran
    Knust, Kristin
    Koreth, John
    Krishnan, Amrita
    Landau, Heather
    Shah, Nina
    Somlo, George
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Vesole, David H.
    McCarthy, Philip L.
    Pasquini, Marcelo C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [38] Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
    De Tute, Ruth
    Pawlyn, Charlotte
    Cairns, David
    Davies, Faith
    Rawstron, Andy
    Jones, John
    Hockaday, Anna
    Menzies, Tom
    Henderson, Rowena
    Cook, Gordon
    Drayson, Mark
    Jenner, Matthew
    Kaiser, Martin
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    Owen, Roger
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S10 - S10
  • [39] EFFECTIVENESS AND TOXICITY OF SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR RELAPSED OR PROGRESSIVE MULTIPLE MYELOMA
    El Fatmi, R.
    Bahri, M.
    Balloumi, D.
    Ben Abdeljelil, N.
    Torjemane, L.
    Lakhal, A.
    Ladeb, S.
    Ben Othman, T.
    HAEMATOLOGICA, 2016, 101 : 856 - 856
  • [40] Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan
    Muta, Tsuyoshi
    Miyamoto, Toshihiro
    Kamimura, Tomohiko
    Kanda, Yoshinobu
    Nohgawa, Masaharu
    Ueda, Yasunori
    Iwato, Koji
    Sasaki, Osamu
    Mori, Takehiko
    Uchida, Naoyuki
    Iida, Shinsuke
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Sunami, Kazutaka
    ACTA HAEMATOLOGICA, 2018, 139 (01) : 35 - 44
12345